U.S. market Open. Closes in 5 hours 21 minutes

GBIO | Generation Bio Co. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 0.4013 - 0.4305
52 Week Range 0.4013 - 4.65
Beta 2.44
Implied Volatility 348.65%
IV Rank 70.38%
Day's Volume 365,598
Average Volume 514,883
Shares Outstanding 67,007,900
Market Cap 27,138,200
Sector Healthcare
Industry Biotechnology
IPO Date 2020-06-12
Valuation
Profitability
Growth
Health
P/E Ratio -0.20
Forward P/E Ratio N/A
EPS -1.98
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 174
Country USA
Website GBIO
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
*Chart delayed
Analyzing fundamentals for GBIO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see GBIO Fundamentals page.

Watching at GBIO technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on GBIO Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙